Marginal Zone Lymphoma Treatment Market: By Treatment Type (Chemotherapy, Radiation Therapy, and Immunotherapy), Route of Administration (Oral and Parental), End User (Specialty Hospitals and Others), and Geography

Marginal Zone Lymphoma Treatment Market was valued at USD 1,397.6 million in 2022 and it is expected to reach USD 840.2 Million by 2028, growing at a 6.2% CAGR from 2023 to 2029. Marginal zone lymphoma is a slow-growing B-cell non-Hodgkin lymphoma that begins forming from certain areas of lymph tissue. There are three regions from where it begins such as the spleen, lymph nodes, and lymphoid tissue that contains a lot of B-cells, marginal zone lymphoma is caused due to H. pylori, a helicobacter bacterium that attacks the lining of the stomach, and the first part of small intestine i.e., duodenum. The risk increases in a person of 65+ age with a weakened immune system. The treatment of marginal zone cell lymphoma is segmented into compounding chemotherapy to kill cancer cells, radiation therapy to shrink tumors, and immunotherapy. The increase in geriatric patient portal and the development of new drug development are the major factors that drive the market in the world. The global geriatric population is expected to increase in the forecast period. According to WHO, the population of the geriatric population will increase from 619 million to 1.5 billion in 2030, various possibilities are to there to infect from such types of cancer. The surge in the hospital and treatment techniques provides maximum opportunity to the hospitals, healthcare providers are launching new treatments and drugs to lower marginal zone lymphoma. The lack of skilled professionals and side effects from lymphoma treatment are major restraints in the marginal zone lymphoma treatment market. Geographically, North America and Europe hold the major market share in 2022 and are expected to dominate the lymphoma treatment market in the forecasted years.

Recent Market Key Developments:
In February 2021, The U.S. Food and Drug Administration (FDA) announced the approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody.